Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | GAA | P10253 | 4/20 | 0.64 |
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22091065 | 0.81 | GAA (0.49) | ALDH1A1GAAIDO1SMN1; SMN2KMT2A | |
| SCHEMBL1621739 | 0.81 | IDO1 (0.68) | MAPTALDH1A1GAAIDO1SMN1; SMN2 | |
| SCHEMBL11445832 | 0.81 | KMT2A (0.69) | MAPTALDH1A1GAAKMT2AGLA | |
| SCHEMBL9690067 | 0.78 | GAA (1.00) | MAPTALDH1A1GAAIDO1KMT2A | |
| SCHEMBL790339 | 0.77 | MEN1 (0.52) | ALDH1A1GAAIDO1KMT2AMEN1 | |
| SCHEMBL20984278 | 0.77 | GAA (0.61) | MAPTALDH1A1GAAIDO1SMN1; SMN2 | |
| SCHEMBL28049803 | 0.76 | CA2 (0.56) | MAPTALDH1A1GAAIDO1SMN1; SMN2 | |
| SCHEMBL163118 | 0.76 | ALDH1A1 (0.61) | MAPTALDH1A1GAASMN1; SMN2KMT2A | |
| SCHEMBL18707358 | 0.76 | GAA (0.50) | MAPTALDH1A1GAAIDO1SMN1; SMN2 | |
| SCHEMBL28032785 | 0.74 | CYP3A4 (0.60) | ALDH1A1GAAIDO1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121687-B1 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-10-14 | — | — | EP | disclosed |
| CN-101679409-B | Bicyclic heterocyclic derivative compounds, pharmaceutical compositions thereof and uses thereof | ASTEX THERAPEUTICS LTD | 2014-11-26 | — | — | CN | disclosed |
| US-8513276-B2 | Imidazo[1,2-a]pyridine compounds for use in treating cancer | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| US-20100093718-A1 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| CN-101679409-A | Novel compounds | ASTEX THERAPEUTICS LTD | 2010-03-24 | — | — | CN | disclosed |
| EP-2121687-A2 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008078100-A2 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093718-A1 | Compounds | FGFR1, FGFR2, PDGFRB | MAPT 3238/4885ALDH1A1 379/4885GAA 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.